These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1706573

  • 1. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
    Wainberg MA, Tremblay M, Rooke R, Blain N, Soudeyns H, Parniak MA, Yao XJ, Li XG, Fanning M, Montaner JS.
    Ann N Y Acad Sci; 1990; 616():346-55. PubMed ID: 1706573
    [No Abstract] [Full Text] [Related]

  • 2. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
    Albert J, Wahlberg J, Lundeberg J, Cox S, Sandström E, Wahren B, Uhlén M.
    J Virol; 1992 Sep; 66(9):5627-30. PubMed ID: 1380098
    [Abstract] [Full Text] [Related]

  • 3. [Resistance to azidothymidine in human immunodeficiency virus (HIV) infection].
    Karmanov EV, Lukashov VV.
    Mol Biol (Mosk); 1994 Sep; 28(1):7-20. PubMed ID: 7511784
    [Abstract] [Full Text] [Related]

  • 4. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 5. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.
    Smith MS, Koerber KL, Pagano JS.
    J Infect Dis; 1993 Feb 27; 167(2):445-8. PubMed ID: 7678429
    [Abstract] [Full Text] [Related]

  • 6. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 7. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
    Mohri H, Singh MK, Ching WT, Ho DD.
    Proc Natl Acad Sci U S A; 1993 Jan 01; 90(1):25-9. PubMed ID: 7678340
    [Abstract] [Full Text] [Related]

  • 8. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
    Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ.
    J Med Virol; 1995 Jul 01; 46(3):238-43. PubMed ID: 7561796
    [Abstract] [Full Text] [Related]

  • 9. [Stability of human immunodeficiency virus to azidothymidine. II. Kinetic characteristics of "AZT-resistant" mutant forms of reverse transcriptase].
    Pokholok DK, Gudima SO, Memelova LV, Esipov DS, Rechinskiĭ VO, Kochetkov SN.
    Biokhimiia; 1996 Jan 01; 61(1):142-51. PubMed ID: 8679772
    [Abstract] [Full Text] [Related]

  • 10. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
    Gashnikova N, Plyasunova O, Kiseleva Y, Fedyuk N, Pokrovsky A.
    Nucleosides Nucleotides Nucleic Acids; 2003 Jan 01; 22(5-8):991-4. PubMed ID: 14565328
    [Abstract] [Full Text] [Related]

  • 11. [Interaction of primers with mutant forms of human immunodeficiency virus reverse transcriptase].
    Zakharova OD, Suturina OA, Gudima SO, Pokholok DK, Iamkovoĭ VI, Kochetkov SN, Nevinskiĭ GA.
    Mol Biol (Mosk); 1996 Jan 01; 30(1):231-40. PubMed ID: 8714140
    [No Abstract] [Full Text] [Related]

  • 12. Nucleoside drug resistance in HIV-1 reverse transcriptase.
    Yadav PN, Yadav JS, Modak MJ.
    Nat Struct Biol; 1995 Mar 01; 2(3):193-5. PubMed ID: 7539709
    [No Abstract] [Full Text] [Related]

  • 13. [Molecular basis and clinical significance of HIV-1 resistance to nucleoside compounds].
    Wainberg MA, Gu Z, Salomon H, Arts EJ, Kleiman L, Parniak MA, Morin N.
    C R Acad Sci III; 1995 Mar 01; 318(3):315-28. PubMed ID: 7540494
    [Abstract] [Full Text] [Related]

  • 14. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Dis Markers; 1990 Mar 01; 8(3):163-4. PubMed ID: 1703061
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of resistance mutants of viral polymerases.
    Oxford JS, al-Jabri AA, Stein CA, Levantis P.
    Methods Enzymol; 1996 Mar 01; 275():555-600. PubMed ID: 9026659
    [No Abstract] [Full Text] [Related]

  • 16. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA, Kemp SD.
    Science; 1989 Dec 01; 246(4934):1155-8. PubMed ID: 2479983
    [Abstract] [Full Text] [Related]

  • 17. Sequence analysis of reverse transcriptase genes of zidovudine (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains.
    Sheehy N, Desselberger U.
    J Gen Virol; 1993 Feb 01; 74 ( Pt 2)():223-8. PubMed ID: 7679140
    [Abstract] [Full Text] [Related]

  • 18. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells.
    Rooke R, Tremblay M, Wainberg MA.
    Virology; 1990 May 01; 176(1):205-15. PubMed ID: 1691885
    [Abstract] [Full Text] [Related]

  • 19. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 20. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development.
    de Clercq E.
    Med Res Rev; 1996 Mar 15; 16(2):125-57. PubMed ID: 8656777
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.